Verrica completes COVE-2 enrolment for YCANTH common warts label

Verrica Pharmaceuticals has completed enrolment in COVE-2, the first of two pivotal Phase 3 trials evaluating YCANTH (VP-102, cantharidin) for the treatment of common warts. An independent per-protocol interim statistical power analysis confirmed that no additional patients are required, and the study remains fully blinded. Topline data are expected in the first quarter of 2027.

The NASDAQ-listed company simultaneously confirmed that its second pivotal study, COVE-3, has exceeded 50% of its current target enrolment ahead of schedule, with topline results anticipated by mid-2027. COVE-3 is enrolling patients in both the United States and Japan, while COVE-2 was a US-only study.

Trial design and commercial rationale

Both COVE-2 and COVE-3 are double-blind, randomised, vehicle-controlled studies assessing VP-102 applied once every 21 days for up to four cycles in patients aged two years and older. The broader programme also includes a long-term follow-up study (COVE-4) and a pharmacokinetics study (COVE-5). Verrica and its Japanese development partner, Torii Pharmaceutical, a wholly owned subsidiary of Shionogi, are splitting costs on a 50/50 basis, with Torii funding the first $40 million of trial costs, representing roughly 90% of the current budget. Verrica's share is expected to be recovered through transfer price payments, milestones and royalties on Japanese YCANTH sales.

Chief medical officer Noah Rosenberg said that patients with common warts "often try minimally effective over-the-counter therapies, with limited success and frequent recurrence," and that a successful Phase 3 programme could make YCANTH "the first FDA-approved prescription drug treatment for common warts, one of the largest unmet needs in dermatology."

Verrica estimates US prevalence at approximately 22 million patients, with around half of those seeking treatment being children. The company describes the addressable market as a potential multibillion-dollar commercial opportunity, though that figure is a company projection and has not been independently validated.

Market context and competitive landscape

Common warts (verruca vulgaris) represent a long-standing gap in the prescription dermatology market. No FDA-approved pharmacological therapy currently exists, leaving dermatologists reliant on destructive procedures such as liquid-nitrogen cryotherapy, salicylic acid preparations, and off-label approaches. YCANTH is already FDA-approved for molluscum contagiosum, giving Verrica an existing commercial infrastructure, a trained salesforce and established payor relationships it intends to leverage for a warts indication if approved.

In the broader prescription dermatology space, competition for dermatologist attention is intensifying, with biologics for atopic dermatitis and psoriasis commanding significant commercial bandwidth. Verrica's positioning in an orphaned procedural niche, backed by a relatively low-cost topical candidate and a cost-sharing partnership with a well-capitalised Japanese partner, differentiates it from larger-molecule competitors. Regulatory read-across from the molluscum approval may inform FDA expectations around study design and endpoints, though the agency has not publicly signalled its requirements for a common warts indication.

The positive outcome of the COVE-2 power analysis is an incremental but meaningful signal: it reduces the risk that enrolment underpowering will force a protocol amendment, and it keeps the programme on its previously stated timeline. Investors will look to the Q1 2027 topline readout as the next material catalyst.